angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- has been researched along with naltrexone in 1 studies
| Studies (angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-) | Trials (angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-) | Recent Studies (post-2010) (angiotensin ii, des-asp(1)-des-arg(2)-ile(5)-) | Studies (naltrexone) | Trials (naltrexone) | Recent Studies (post-2010) (naltrexone) |
|---|---|---|---|---|---|
| 311 | 5 | 64 | 8,745 | 1,228 | 2,642 |
| Protein | Taxonomy | angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- (IC50) | naltrexone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 1 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.0051 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0063 | |
| Kappa-type opioid receptor | Mus musculus (house mouse) | 0.006 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.006 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.0319 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0093 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0377 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0076 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ebinger, G; Fournié-Zaluski, MC; Michotte, Y; Sarre, S; Stragier, B; Vanderheyden, P; Vauquelin, G | 1 |
1 other study(ies) available for angiotensin ii, des-asp(1)-des-arg(2)-ile(5)- and naltrexone
| Article | Year |
|---|---|
Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Hemoglobins; Imidazoles; Male; Methionine; Microdialysis; Naltrexone; Narcotic Antagonists; Peptide Fragments; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 2; Sulfonic Acids; Tetrazoles; Time Factors | 2004 |